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Abstract : Objective : The effects of miglitol on postprandial glucose and 
lipid metabolism were investigated in patients with type 2 diabetes mellitus 
（T2DM） treated with diet alone.  Subjects and Methods : A meal tolerance 
test （MTT） was performed in 26 diabetic patients before and 2 weeks after 
150 mg / day miglitol treatment, with the second MTT performed in patients 
after they had taken a dose of 50 mg miglitol.  Results : Miglitol treatment 
decreased postprandial blood glucose and serum insulin levels 30 and 60 min 
after meal loading, but there was no change in blood glucose levels at 120 
min.  In addition, there were no significant decreases in the area under the 
curve （AUC） of blood glucose and serum insulin levels.  However, the AUC 
of postprandial serum triglycerides and incremental triglycerides decreased 
signicantly, as did the AUC of postprandial incremental remnant-like particle 
cholesterol.  There were no signicant changes in total cholesterol, high-density 
lipoprotein-cholesterol and low-density lipoprotein-cholesterol.  Conclusions : 
Miglitol treatment improves postprandial hyperlipidemia, as well as postpran-
dial hyperglycemia, in patients with T2DM.  In T2DM patients treated with  
α-glucosidase inhibitors alone, measuring blood glucose levels 120 min after 
a meal may not be the best way to monitor postprandial glucose metabo-
lism.
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Introduction
　Large prospective observational studies consistently show that 1 to 2-h post-glucose chal-
lenge levels are better predictors of the risk of coronary heart disease （CHD） than fasting 
glucose1-3）.  In Japan, the Funagata Diabetes study reported that impaired glucose tolerance 
（IGT）, but not impaired fasting glucose （IFG）, is a risk factor for cardiovascular disease 4）. 
Transient increases in blood glucose induce and accelerate endothelial dysfunction, oxidant 
stress5）, and hypercoagulability, and suppress nitric oxide （NO） production 6）.  In addition, 
postprandial hypertriglyceridemia has been reported to independently increase the incidence 
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of myocardial infarction 7-11）.  Postprandial hyperlipidemia is often associated with elevated 
plasma levels of the remnant lipoprotein fraction, the appearance of small, dense low-density 
lipoprotein （LDL）, and a decrease in high-density lipoprotein-cholesterol （HDL-C）.  The 
postprandial state characterized by abnormally increased glucose and lipid levels has been 
referred to as “postprandial dysmetabolism” 12）.  α-Glucosidase inhibitors have been reported 
to treat postprandial hyperglycemia and hypertension, as well as to suppress the incidence 
of cardiovascular events13）.  In a previous study we showed that acarbose, an α-glucosidase 
inhibitor, suppresses plasma levels of the remnant fraction in the fasting state14）.  Thus, the 
aim of the present study was to determine whether miglitol, one of the new α-glucosidase 
inhibitors15, 16）, can improve postprandial hyperglycemia and hyperlipidemia simultaneously in 
patients with type 2 diabetes mellitus （T2DM） treated by diet alone.  To assess postprandial 
glucose and lipid metabolism simultaneously we used “Test meal A”, which was designed by 
the Japan Diabetes Society Test Meal Development Working Group 17）.
Methods
Study subjects
　Twenty-six T2DM patients treated with diet alone and without a history of cardiovascular 
complications, hepatic disorders, thyroidal dysfunction, and renal failure were enrolled in 
the present study.  None of the patients had taken any hypoglycemic or antihyperlipidemic 
agents, or had had insulin injections.  All of the diabetic patients were Japanese and all 
were outpatients of Toho University Omori Medical Center and Makita General Hospital. 
In addition, six non-diabetic healthy volunteers were enrolled in the study.  All subjects 
provided written informed consent prior to participating in the study.  None of the subjects 
received any compensation for participating in the study.  The baseline characteristics of the 
subjects are given in Table 1.  The mean ± SD age of the T2DM patients and healthy vol-
unteers was 57.5 ± 3.6 （range 29-74） and 37.5 ± 8.0 years, respectively ; their mean ± SD body 
mass index was 26.7 ± 1.3 and 21.9 ± 1.8 kg / m2, respectively ; and the mean ± SD glycosy-
lated hemoglobin （HbA1c） of the T2DM patients was 6.89 ± 0.22％.  Two diabetic patients 
had simple retinopathy, whereas microalbuminuria was detected in another two.  None of 
the patients had any sensory disturbance.
Table 1.  Baseline characteristics of the study subjects
Diabetic subjects Healthy volunteers
Number （male / female）
Age （years）
Body mass index （kg / m2）
Glycosylated A1c （％）
26（13 / 13）




37.5 ± 8.0 （26-49）
21.9 ± 1.8
（Mean±SD）
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Methodology
　The study protocol was approved by the Ethics Committee of the Toho University Omori 
Medical Center and Makita General Hospital.  In the present study, we used “JANEFF48” 
（Kewpie, Tokyo, Japan） as the test meal, which is produced according to the menu of 
“Test meal A” designed by the Japanese Diabetes Society Test Meal Development Working 
Group17）.  The meal contains a soft pudding, cracker, and cream chicken stew, with 460 kcal 
total energy （carbohydrates 51.4％, lipids 33.3％, and proteins 5.3％）.  On the first day of 
the study, diabetic patients and healthy volunteers visited our hospital after 12 h fasting and 
underwent blood tests.  They were then given the test meal with 100 mL water to consume 
in 15 min.  They then underwent further blood testing at 30, 60, 90, 120, and 180 min after 
meal loading.  Thereafter, only the diabetic patients were started on 50 mg miglitol （Sanwa 
Kagaku Kenkyusho, Tokyo, Japan）, to be taken before each meal, three times a day, for 2 
weeks.  The second meal tolerance test was performed with only diabetic patients in the 
same manner, with taking 50 mg miglitol before consuming the test meal （Fig. 1）.
Biochemical measurements
　In the present study, HbA1c values （％） were estimated as Japan Diabetes Society ［JDS］ 
equivalent values （％） calculated using the formula HbA1c （％）＝HbA1c （National Glyco-
hemoglobin Standardization Program ［NGSP］） （％）-0.4（％）, based on previous determina-
tions of the relationship between HbA1c （JDS） （％）, as measured by Japanese standard 
substance and measurement methods, and HbA1c （NGSP）18）.  Blood glucose levels were 
measured using the glucose-oxidase method, whereas serum insulin levels were determined 
as the Chemiluminescent Immuno Assay （CLIA）.  Serum lipid levels were measured using 
an autoanalyzer and serum remnant-like particle cholesterol （RLP-C） levels were determined 
using an immunoafnity column19）.
Statistical analysis
　Data were checked for normal distribution.  Data during the meal tests were analyzed 
by repeated-measures analysis of variance （ANOVA）.  Data were also analyzed using Steel’s 
Fig. 1.  Protocol for the meal tolerance test.
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multiple comparison test for multiple related samples.  All analyses were performed using 
SPSS software package （IBM Corp.）, and significance was set at 0.05.  In case of cor-
respondence, data were analyzed using Student’s t-test and paired t-test.  The area under 
the curve （AUC） was estimated by calculating the sum of the area between each sampling 
point.  Comparisons of AUCs were made using paired t-tests.
Results
　The most common adverse gastrointestinal tract events associated with α-glucosidase 
inhibitors are flatulence, diarrhea, and abdominal pain.  In the present study, all diabetic 
patients tolerated miglitol well and no adverse events were observed.
　Blood glucose levels of diabetic patients were signicantly higher at every sampling point 
than those in healthy volunteers, with a peak at 60 min after the test meal in T2DM 
patients （Fig. 2a）.  Serum insulin peaked at 90 min after the test meal in diabetic patients, 
compared with a peak at 30 min in healthy volunteers （Fig. 2b）.
　After miglitol treatment, fasting blood glucose level did not change, but the peak in 
postprandial blood glucose levels shifted from 60 to 90 min, but did not change at all at 
120 min.  In addition, miglitol treatment significantly decreased postprandial blood glucose 
levels （P＜0.01, repeated-measures ANOVA ; Fig. 2a）.  Following miglitol treatment, post-
prandial blood glucose at 30 and 60 min decreased from 170.9 ± 5.4 to 142.7 ± 6.2 mg / dL 
and from 188.7 ± 7.2 to 170.2 ± 7.5 mg / dL, respectively （P＜0.001 and P＜0.05, paired t-test, 
respectively）.  There was a tendency for the AUC of blood glucose （0-3 h） to decrease 
from 475.2 ± 17.1 to 444.3 ± 14.9 mg·h / dL after miglitol treatment, but the difference failed 
to reach statistical significance.  In contrast, there was a significant decrease in the AUC of 
incremental blood glucose （0-3 h） from 114.3 ± 26.9 to 80.4 ± 23.3 mg·h / dL after miglitol 
treatment （P＜0.05, paired t-test ; Table 2）.
　Miglitol treatment of diabetic patients significantly decreased postprandial serum insulin 
levels （P＜0.01, repeated-measures ANOVA ; Fig. 2b）.  Specifically, significant decreases 
were seen after miglitol treatment in serum insulin levels at 30 min （from 26.4± 5.0 to 16.6±
2.8 μU / mL ; P＜0.001, paired t-test）, 60 min （from 36.0 ± 6.7 to 21.6 ± 2.8 μU / mL ; 
P＜0.05, paired t-test）, and at 90 min after the test meal （from 37.0 ± 6.6 to 24.9 ± 2.5 μU /
mL ; P＜ 0.05, paired t-test）.  Although there was a tendency for the AUC of serum insulin 
（0-3 h） to decrease after miglitol treatment （from 87.3 ± 14.7 to 64.9 ± 8.2 U·h / dL）, the 
difference failed to reach statistical significance.  However, miglitol treatment significantly 
decreased the AUC of incremental serum insulin （0-3 h） from 70.0 ± 18.8 to 44.3 ± 12.4 
U·h / dL （P＜0.05, paired t-test ; Table 2）.  Miglitol treatment also decreased the homeosta-
sis model assessment for insulin resistance （HOMA-R） from 2.56 ± 3.02 to 2.24 ± 1.88 （P＝
0.0756）.
　After miglitol treatment, there was a tendency for postprandial serum triglyceride and 
incremental triglyceride to decrease, but the differences were not significant （P＞0.05, 
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Fig. 2.  （a） Blood glucose, （b） serum insulin, （c） serum triglyceride, （d） incremental triglyceride, （e） serum 
remnant-like particle cholesterol （RLP-C）, and （f） incremental RLP-C levels in diabetic patients and 
healthy volunteers during the meal tolerance test. Open and closed circles represent values obtained 
from diabetic patients （n＝26） before and after miglitol treatment, respectively. Open triangles represent 
values obtained from healthy volunteers （n＝6）. Data are expressed as the mean ± SD. Statistical 
signicance was analyzed by repeated-measures ANOVA, and Student’s t-test and paired t-test in case 
of correspondence. ＊P＜0.05, ＊＊P＜0.01, ＊＊＊P＜0.001 compared with before miglitol treatment ; †P＜
0.05, ††P＜0.01, †††P＜0.001 compared with the 0 min time point before miglitol treatment ; ‡P＜0.05, 
‡‡P＜0.01, ‡‡‡P＜0.001 compared with the 0 min time point after miglitol treatment ; §P＜0.05, §§P＜
0.01, §§§P＜0.001 compared with the 0 min time point in healthy volunteers.
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repeated-measures ANOVA ; Fig. 2c, d）.  However, miglitol treatment produced significant 
decreases in the AUC （0-3 h） of serum triglyceride from 418.4 ± 39.0 to 367.5 ± 33.9 mg·h /
dL （P＜0.05, paired t-test ; Table 2） and incremental triglyceride from 79.2 ± 12.8 to 58.1 ±
10.0 mg·h / dL （P＜0.05, paired t-test ; Table 2）.
　Serum RLP-C and incremental RLP-C levels increased gradually after test meal loading 
in diabetic patients （repeated-measures ANOVA ; Fig. 2e, f）.  Miglitol treatment signicantly 
decreased the AUC of incremental serum RLP-C （0-3 h） from 4.4 ± 0.8 to 2.6 ± 0.6 mg·h /
dL （P＝0.005, paired t-test ; Table 2）.  Miglitol treatment had no effect on postprandial 
levels of total cholesterol, HDL-C, and LDL-C.
Discussion
　To assess postprandial glucose and lipid metabolism simultaneously, we used the “JANEF 
F48” meal （Kewpie）, which was produced according to the formula of “Test Meal A”.  To 
characterize glucose and lipid excursions after test meal loading in diabetic patients, we 
also performed test meal loading in non-diabetic healthy subjects.  Blood glucose levels of 
diabetic patients at every sampling point were signicantly higher than those in the healthy 
volunteers, with the peak shifted from 30 to 60 min.  The serum insulin peak was shifted in 
diabetic patients from 30 to 90 min.  Thus, this test meal loading is suitable for the investi-
gation of blood glucose and insulin responses in patients with mild diabetes.
　In diabetic patients, possibly because of a suppressed blood glucose response caused by 
miglitol, postprandial serum insulin levels decreased significantly （Fig. 2b）.  Thus, miglitol 
treatment may have favorable effects in diabetic patients from the viewpoint of insulin 
resistance.  In support of this, average HOMA-R decreased to below 2.5, which is the lower 
Table 2.  The area under the curve （AUC 0-3hr） of study parameters in healthy volunteers, and diabetic 





2 weeks after 
Miglitol treatment
p value
Blood Glucose （mg·hr / dl） 268.0 ± 16.6 475.2 ± 17.1 444.3 ± 14.9 0.0501
Incremental Blood Glucose （mg·hr / dl） 33.0 ± 13.5 114.3 ± 26.9 80.4 ± 23.3 0.0226
Serum Insulin （μU·hr / dl） 62.6 ± 7.0 87.3 ± 14.7 64.9 ± 8.2 0.0504
Incremental Serum Insulin （μU·hr / dl） 49.36 ± 7.4 70.0 ± 18.8 44.3 ± 12.4 0.0164
Triglyceride （mg·hr / dl） 308.4 ± 79.7 418.4 ± 39.0 367.5 ± 33.9 0.0359
Incremental triglyceride （mg·hr / dl） 60.9 ± 21.0 79.2 ± 12.8 58.1 ± 10.0 0.0489
RLP-cholesterol （mg·hr / dl） 14.6 ± 2.6 17.4 ± 1.4 17.7 ± 1.9 0.8468
Incremental RLP-cholesterol （mg·hr / dl） 3.5 ± 1.2 4.4 ± 0.8 2.6 ± 0.6 0.0050
All data are expressed as the mean ± SD. The number in parenthesis indicates the subject number. Signicant 
differences between before and after treatment in diabetic subjects are indicated by p values （paired t-test was 
employed）.
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limit for the presence of insulin resistance according to the recommendations of the Japa-
nese Diabetes Society20）.
　Miglitol treatment shifted the peak of postprandial blood glucose levels from 60 to 90 
min in diabetic patients （Fig. 2a）.  However, as indicated in Table 2, miglitol did not 
decrease the AUC of blood glucose （0-3 h）.  It has been suggested that the effect of 
miglitol is only to delay carbohydrate absorption21）.  Most of the carbohydrates in the small 
intestine may be digested within 3 h, despite miglitol treatment.
　In diabetic patients, the peak of postprandial glucose shifted from 60 to 90 min after 
meal, whereas levels at 120 min did not change at all after miglitol treatment （Fig. 2a）. 
The International Diabetes Federation （IDF） Guidelines for the Management of Postmeal 
Glucose 22） recommend monitoring 2-h postprandial glucose levels for the prevention of car-
diovascular events.  However, it may be inappropriate to monitor 2-h glucose levels during 
treatment with α-glucosidase inhibitors alone because of a shift in the timing of the blood 
glucose peak.  On the basis of the results of the present study, we recommend monitoring 
1-h postprandial glucose levels during treatment with α-glucosidase inhibitors.
　Although it is known that 2-h postprandial hyperglycemia is related to chronic complica-
tions of diabetes and is currently used in international guidelines to drive therapy 22）, Esposi-
to et al have reported that incremental glucose peaks （IGP） in the everyday life of patients 
with T2DM occur for most patients （95％） within 1 h after a meal 23）.  Furthermore, they 
suggested that there is a good correlation between IGP and carotid intima-media thickness, 
and that the timing of the IGP is not inuenced by treatment （diet or drugs）.  These nd-
ings support our proposal to monitor 1-h post-meal glucose levels.
　After miglitol treatment, the AUC of serum triglycerides decreased signicantly in diabetic 
subjects （Table 2）.  It is possible that slowing of monosaccharide absorption by miglitol 
may result in the suppression of triglyceride production in the small intestine.  In diabetic 
patients, serum RLP-C levels after test meal loading did not change with miglitol treat-
ment （Fig. 2d）.  However, if we estimate the incremental RLP-C from Time 0, the RLP-C 
increment was suppressed at 30, 60, 90, and 120 min following treatment （Fig. 2f）.  It is of 
interest that miglitol suppressed the post-meal RLP-C levels in diabetic patients.  Because a 
single dose of acarbose, another α-glucosidase inhibitor, cannot suppress postprandial triglyc-
eride levels in diabetic patients24） and insulin-resistant states are known to induce overpro-
duction of chylomicron from the small intestine25）, it is speculated that improvement of the 
insulin resistant state following 2 weeks treatment with miglitol may result in suppression of 
post-meal increases in RLP-C levels.
　The postprandial state characterized by abnormally increased levels of glucose and lipids 
（also referred to as postprandial dysmetabolism） is now proposed to be an independent 
predictor of future cardiovascular events12）.  Yokoyama et al reported that miglitol treatment 
increased adiponectin levels and decreased the urinary albumin excretion rate in T2DM 
patients26）.  Suppression of the postprandial glucose spike may protect diabetic patients 
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against the development of early stage renal damage and may also increase adiponectin 
secretion from adipocytes.  These possibilities warrant further investigation.
　Large swings in glucose concentrations in the culture medium of human umbilical vein 
cells have been reported to stimulate cell apoptosis 27）.  Furthermore, Mita et al reported that 
the area of the arteriosclerotic lesion in ApoE-deficient mice decreased after miglitol treat-
ment28）.  It is possible that in ApoE-decient mice miglitol treatment minimized the glucose 
swing, thereby decreasing the area of arteriosclerotic lesions.
　In conclusion, miglitol treatment improved not only postprandial glucose, but also triglyc-
eride and remnant lipoprotein metabolism in T2DM patients who were not able to optimize 
glucose control by diet alone.  The findings of the present study suggest that miglitol may 
have a benecial effect in preventing atherogenesis in T2DM by improving postprandial dys-
metabolism.  Furthermore, it is of noteworthy that monitoring 2-h post-meal glucose levels is 
not suitable in diabetic patients being treated with α-glucosidase inhibitors alone.  In these 
patients, it is recommended that 1-h post-meal glucose levels are monitored instead of 2-h 
levels.
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